医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Macrogen Introduces Latest Service Portfolio and Presents Research Outcome at 2014 ASHG Annual Meeting

2014年10月18日 AM01:00
このエントリーをはてなブックマークに追加


 

SAN DIEGO, Calif. & SEOUL, South Korea

The integrated genomic service provider, Macrogen (www.macrogen.com) (KRX 038290) has announced its plans to launch new service portfolio and hold an academic seminar at the annual meeting of the American Society of Human Genetics (ASHG).

Marking its 64th event this year, the 2014 ASHG (www.ashg.org/2014meeting) annual meeting will be held in San Diego on October 18th-22nd, 2014. As the world’s largest conference and exhibition on human genetics, ASHG will host more than 6,500 researchers and 200 enterprises, where they will share their latest research findings and introduce new products and services.

Macrogen plans to officially launch ‘The Macrogen Long-Read Sequencing Service Portfolio’ at this year’s ASHG. The new service line will be capable of analyzing more than 10kb of DNA, facilitating the analysis of structural and cell variation that was not possible with the conventional sequencing technology. The longer read length is ideal for de novo sequencing research, where the specific genome data is being sequenced for the first time, as well as genomic aberration researches for animals, plants, and bacteria. This service will be based on Illumina’s TruSeq Synthetic Long-Read DNA library preparation kit and Pacific Biosciences of California’s SMRT® (Single Molecule, Real-Time) sequencing technology. Macrogen has been cooperating closely with global sequencing equipment suppliers including Illumina Inc. and Pacific Biosciences of California Inc. to build this portfolio. Especially in the SMRT® sequencing technology, Macrogen will be one of the first service provider to use the latest P6-C4 chemistry which represents 6th generation of polymerase and 4th generation of sequencing reagents, which was recently announced by Pacific Biosciences Inc.

“We are thrilled to launch our Long Read Sequencing Portfolio at this year’s ASHG,” said HyungTae, Kim, CEO of Macrogen. “We plan to use this new service portfolio as a launch pad for more aggressive marketing and sales for this year and throughout 2015.”

Furthermore, Macrogen plans to hold a seminar titled “Next Generation Sequencing: A Key to New Discoveries” on October 18th for researchers participating in the annual ASHG meeting. The seminar will feature a keynote lecture by Dr. Michael Snyder, chair-professor of the Department of Genetics at Stanford University and director of Stanford Center for Genomics and Personalized Medicine.

In addition to its marketing activities, Macrogen will present its own research results on in-house developed inherited disease panel. (Poster title: 2538M: Performance evaluation of inherited disease panels for Korean patients with limb-girdle muscular dystrophies (LGMD)).

Macrogen is showcasing its latest genomics service portfolio at 2014 ASHG, booth 1130. For further information about Macrogen seminar and service, contact our sales staff at susanchung@macrogenlab.com and ngs@macrogen.com.

About Macrogen

Macrogen, Inc. (www.macrogen.com), based in Seoul, Korea, is a world leading service provider in high-quality gene analysis and has enjoyed stable and steady growth since 1997. Macrogen Inc. has been dedicated to provide a reliable and efficient service of DNA Sequencing and bioinformatics with profound knowledge and unbeatable amount experience over 17 years. The company’s diverse offerings include DNA sequencing, next generation sequencing, microarray analysis, oligonucleotide synthesis, DNA chip and genetically engineered mice services. We serve over +17,000 customers from academic research and industry in 120 countries around the globe and have subsidiary companies in USA, Japan and Europe, headquartered in South Korea. Find out more at http://www.macrogen.com

CONTACT

Macrogen Inc.
Yonghwan Kang, +82-2-2113-7113
snatch@macrogen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent